HCP
CYTK icon

Hexagon Capital Partners’s Cytokinetics CYTK Stock Holding History

Hexagon Capital Partners’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-6
Closed -$196 – 1426
2023
Q2 		$196 Hold
6
– – ﹤0.01% 1350
2023
Q1 		$211 Hold
6
– – ﹤0.01% 1352
2022
Q4 		$275 Buy
+6
New +$258 ﹤0.01% 1357

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Hexagon Capital Partners's CYTK Position: Q3 2023 in Review

Hexagon Capital Partners sold out of Cytokinetics (CYTK) in Q3 2023, closing a stake of 6 shares — an estimated $196 sold.

Hexagon Capital Partners first reported a position in CYTK in Q4 2022 and held it in 3 quarters. The position peaked at $275 in Q4 2022. 250 funds tracked by Wall St. Rank hold CYTK as of Q3 2023.

  • Hexagon Capital Partners reported no remaining Cytokinetics position as of Q3 2023 after selling out during the quarter.
  • Hexagon Capital Partners sold 6 Cytokinetics shares in Q3 2023, an estimated $196.
  • Hexagon Capital Partners first reported a position in Cytokinetics in Q4 2022 and held it in 3 quarters.
  • Hexagon Capital Partners's Cytokinetics position peaked at $275 in Q4 2022.
  • 250 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2023.

Based on Hexagon Capital Partners's 13F filing for Q3 2023, filed 23 Oct 2023.